Trial reportScandinavian journal of gastroenterology2019
Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Trial report in Scandinavian journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Curcumin-based compounds in non-malignant biliary injury and cholangiocarcinoma: mechanistic insights and translational barriers.Frontiers in pharmacology · 2026Review
- Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.Cancer biology & therapy · 2023Article
- Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials.ACS pharmacology & translational science · 2023Review
- Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.International journal of molecular sciences · 2023Article
- The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation.International journal of molecular sciences · 2022Review
- Review
- Mechanistic Insight into the Effects of Curcumin on Neuroinflammation-Driven Chronic Pain.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities.Journal of clinical medicine · 2021Review
- Obstacles against the Marketing of Curcumin as a Drug.International journal of molecular sciences · 2020Review
- Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.The American journal of gastroenterology · 2020Review
- The Potentiality of Herbal Remedies in Primary Sclerosing Cholangitis: FromFrontiers in pharmacology · 2020Review
- An update on treatment options for primary sclerosing cholangitis.Gastroenterology and hepatology from bed to bench · 2020Review
- Potential of Curcumin in Skin Disorders.Nutrients · 2019Review
- Evaluation of the effects of additional therapy withAvicenna journal of phytomedicineArticle
- An overview of recent treatment options for primary sclerosing cholangitis.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.